Study of paracetamol 1-g oral solution bioavailability

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 1, 2008, Pages 37-41

  Farré, Magí ^a,b   Roset, P N ^a,b,c   Abanades, S ^a,b   Menoyo, E ^a,b   Alvarez, Y ^a,b   Rovira, M ^d   Baena, A ^c  

^a Barcelona Biomedical Research Park   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c SL   (Spain)

^d MCC Analitica   (Spain)

Author keywords

Absorption; Bioavailability; Healthy volunteers; Oral solution; Paracetamol; Pharmacokinetics

Indexed keywords

ANALGESIC AGENT; PARACETAMOL;

ADULT; ANALGESIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 40849130264     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2008.30.1.1159648     Document Type: Article

References (35)

1. Prescott, L.F. Acetaminophen (Paracetamol). A critical bibliographic review. London: Taylor & Francis 1996.
2. Berde, C.B., Sethna, N.F. Analgesics for the tratment of pain in children. New Engl J Med 2002, 347: 1094-103.
3. Farré, M., Abanades, S., Álvarez, Y., Barrai, D., Roset, P.N. Paracetamol. Dolor 2004, 19: 5-15.
4. Whelton, A. Appropriate analgesia: An evidence-based evaluation of the role of acetaminophen in pain management. Am J Ther 2005, 12: 43-5.
5. 2 synthases. Clin Pharmacol Ther 2006, 79: 9-19.
6. Ruoff, G. Management of pain in patients with multiple health problems: A guide for the practicing physician. Am J Med 1998, 105(1B): 53S-60S.
7. Litauen, C., Jacqz-Aigrain, E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children. Paediatr Drugs 2001, 3: 817-58.
8. Briggs, G.G., Freeman, R.K., Yaffe, S.J. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk (6th ed.). Philadelphia: Lippincott Williams & Wilkins 2002.
9. le Parc, J.M., van Ganse, E., Moore, N., Wall, R., Schneid, H., Verriere, F. Comparative tolerability of paracetamol, aspirin and Ibuprofen for short-term analgesia in patients with musculoskeletal conditions: Results in 4291 patients. Clin Rheumatol 2002, 21: 28-31.
10. Lewis, S.C., Langman, M.J., Laporte, J.R., Matthews, J.N., Rawlins, M.D., Wiholm, B.E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002, 54: 320-6.
11. Aronson, J.K. (Ed.). Meyler's Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions (15th ed.). Amsterdam: Elsevier 2006.
12. Barden, J., Edwards, J., Moore, A., McQuay, H. Single dose oral paracetamol (acetaminophen) for postoperative pain. Cochrane Database Syst Rev 2004, (1): CD004602.
13. Towheed, T.E., Maxwell, L., Judd, M.G., Catton, M., Hochberg, M.C., Wells, G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, (1): CD004257.
14. Temple, A.R., Benson, G.D., Zinsenheim, J.R., Schweinle, J.E. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther 2006, 28: 222-35.
15. Bannwarth, B., Péhourcq, F. Bases pharmacologiques de l'emploi du paracétamol: Aspects pharmacocine'tiques et pharmacodynamiques [Pharmacologic basis for using paracetamol: Pharmacokinetic and pharmacodynamic issues]. Drugs 2003, 63(Spec Iss 2): 5-13.
16. Baños, J.E. Antécédentes históricos del paracetamol [Historical records of paracetamol]. Jano 1995, 49: 1137.
17. Farré, M., Roset, P.N., Pascual, J.A. et al. Estudio de la velocidad de absorción y de la biodisponibilidad de Gelocatil comprimidos 650 mg [Bioavailability and speed of absorption study of Gelocatil 650 mg tablets]. Dolor 2001, 16: 27-32.
18. Farré, M., Roset, P.N., Pascual, J.A. et al. Estudio de la velocidad de absorción y de la biodisponibilidad de paracetamol en solución oral [Bioavailability and speed of absorption study of paracetamol oral solution]. Dolor 2002, 17: 15-18.
19. Prakongpan, S., Puncoke, R., Nagai, T. Comparative bioavailability study of acetaminophen solutions used in hospital formulary. Biol Pharm Bull 1993, 16: 613-5.
20. Grattan, T., Hickman, R., Darby-Dowman, A., Hayward, M., Boyce, M., Warrington, S. A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate. Eur J Pharm Biopharm 2000, 49: 225-9.
21. Rygnestad, T., Zahlsen, K., Sandal, F.A. Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. Eur J Clin Pharmacol 2000, 56: 141-3.
22. Sevilla-Tirado, F.J., González-Vallejo, E.B., Leary, A.C., Breedt, H.J., Hyde, V.J., Fernandez-Hernando, N. Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. Methods Find Exp Clin Pharmacol 2003, 25: 531-5.
23. Sutton, J.A., Gillin, W.P., Grattan, T.J., Clarke, G.D., Kilminster, S.G. A new laser pain threshold model detects a faster onset of action from a liquid formulation of 1 g paracetamol than an equivalent tablet formulation. Br J Clin Pharmacol 2002, 53: 43-7.
24. Nielsen, J.C., Bjerring, P., Arendt-Nielsen, L., Petterson, K.J. Analgesic efficacy of immediate and sustained release paraceta mol and plasma concentration of paracetamol. Double blind, placebo-controlled evaluation using painful laser stimulation. Eur J Clin Pharmacol 1992, 42: 261-4.
25. Moller, P.L., Norholt, S.E., Ganry, H.E. et al. Time to onset of analgesia and analgesic efficacy of effervescent acetaminophen 1000 mg compared to tablet acetaminophen 1000 mg in postoperative dental pain: A single-dose, double-blind, randomized, placebo-controlled study. J Clin Pharmacol 2000, 40: 370-8.
26. Anderson, B.J., Gibb, I.A. Paracetamol (acetaminophen) pharmacodynamics; interpreting the plasma concentration. Arch Dis Child 2008 [published online 2007 Sep 6, doi:10.1136/adc.2007.126896].
27. He, F.J., MacGregor, G.A. How far should salt intake be reduced? Hypertension 2003, 42: 1093-9.
28. Meneton, P., Jeunemaitre, X., de Wardener, H.E., MacGregor, G.A. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005, 85: 679-715.
29. Cook, N.R., Cutler, J.A., Obarzanek, E. et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334: 885.
30. Anonymous. Los cardiólogos recomiendan a sus pacientes hipertensos evitar el consumo de fármacos con alto contenido en sodio [Cardiologists warn their patients to avoid medicinal products with high sodium contents]. Sístole Hipertensión 2001, 238: 40.
31. Berbel León, S., Franco, H.I. Miocardiopatía dilatada: A propósito de un caso [Dilated cardiomyopathy: a case study]. Medifam 2003, 13: 314-19.
32. Geddes, C.C., Houston, M., Pediani, L., Munday, A., Woo, Y.M. Excess interdialytic sodium intake is not always dietary. Nephrol Dial Transplant 2003, 18: 223-4.
33. Sanz, V.P., Moreno, E.O., Martínez, B.Z., Gutiérrez, F.M. Una mala elección [A bad choice]. Med Gen 2004, 65: 380-1.
34. Douglas, L., Akil, M. Sodium in soluble paracetamol may be linked to raised blood pressure. BMJ 2006, 332: 1133.
35. Sweetman, S.C. Martindale. Guía completa de consulta farmaco-terapéutica [The complete drug reference] (2nd ed.). Barcelona: Pharma Editores 2006.